Ultragenyx PharmaceuticalRARE
About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Employees: 1,294
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
29% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 42
4% more funds holding
Funds holding: 298 [Q3] → 309 (+11) [Q4]
1.69% more ownership
Funds ownership: 93.24% [Q3] → 94.93% (+1.69%) [Q4]
2% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 108
17% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]
17% less call options, than puts
Call options by funds: $31.5M | Put options by funds: $37.9M
23% less capital invested
Capital invested by funds: $4.77B [Q3] → $3.68B (-$1.09B) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Morgan Stanley Jeffrey Hung 15% 1-year accuracy 4 / 26 met price target | 83%upside $65 | Overweight Maintained | 9 May 2025 |
JP Morgan Anupam Rama 21% 1-year accuracy 12 / 57 met price target | 229%upside $117 | Overweight Maintained | 27 Mar 2025 |
Piper Sandler Allison Bratzel 45% 1-year accuracy 5 / 11 met price target | 223%upside $115 | Overweight Maintained | 17 Mar 2025 |
Cantor Fitzgerald Kristen Kluska 28% 1-year accuracy 27 / 97 met price target | 231%upside $118 | Overweight Reiterated | 26 Feb 2025 |
HC Wainwright & Co. Ed Arce 38% 1-year accuracy 51 / 134 met price target | 167%upside $95 | Buy Reiterated | 18 Feb 2025 |
Financial journalist opinion
Based on 11 articles about RARE published over the past 30 days
